{"title":"A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra).","authors":"Rajiv Mallick, Rashad Carlton","doi":"10.1007/s41669-025-00594-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary immune deficiency (PID) comprises over 400 inborn errors of immunity. Immune globulin replacement therapy (IGRT) is the standard of care for many PID subtypes. Intravenous immunoglobulin (IVIG) is the historic standard of care, but subcutaneous immunoglobulin (SCIG) offers several advantages for IGRT. Further, a novel pre-filled syringe (PFS) drug packaging form of SCIG is expected to facilitate more efficient patient infusions.</p><p><strong>Objective: </strong>The aim of this study was to quantify the projected budget impact associated with adding the IgPro20 PFS as an SCIG drug packaging option to a health plan formulary for the treatment of PID.</p><p><strong>Methods: </strong>A budget impact model (BIM) was developed across the United States (US) integrated delivery networks (IDNs)' perspective over a 3-year time horizon to quantify the projected budget impact of adding the IgPro20 PFS as an SCIG packaging option for the treatment of PID. Model comparators included six IVIGs and seven SCIGs. A one-way sensitivity analysis was conducted to assess the impact of model parameters on the budget impact. Scenario analyses of alternative market share shifts and pricing were conducted to test the robustness of the model results.</p><p><strong>Results: </strong>From the perspective of an IDN with 25 million members, the average annual expected cost per PID patient was US$73,343 for IgPro20 vials w/pump, US$60,892 for IgPro20 PFS w/pump, US$72,179 for IVIG, and US$96,581 for other SCIGs. Assuming market share uptake of 6.0% in the first year for IgPro20 PFS w/pump, rising to 8.4% by year 3, and offset by corresponding proportionate reductions in shares of the non-PFS SCIG IgPro20 vials w/pump only, the expected incremental budget impact over the 3-year horizon was savings of US$10.5 million.</p><p><strong>Conclusion: </strong>This BIM demonstrates that uptake of subcutaneous IgPro20 PFS is expected to be associated with substantial savings for a US IDN, including drug cost savings if offset by reduced non-PFS SCIG-packaging use.</p>","PeriodicalId":19770,"journal":{"name":"PharmacoEconomics Open","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41669-025-00594-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Primary immune deficiency (PID) comprises over 400 inborn errors of immunity. Immune globulin replacement therapy (IGRT) is the standard of care for many PID subtypes. Intravenous immunoglobulin (IVIG) is the historic standard of care, but subcutaneous immunoglobulin (SCIG) offers several advantages for IGRT. Further, a novel pre-filled syringe (PFS) drug packaging form of SCIG is expected to facilitate more efficient patient infusions.
Objective: The aim of this study was to quantify the projected budget impact associated with adding the IgPro20 PFS as an SCIG drug packaging option to a health plan formulary for the treatment of PID.
Methods: A budget impact model (BIM) was developed across the United States (US) integrated delivery networks (IDNs)' perspective over a 3-year time horizon to quantify the projected budget impact of adding the IgPro20 PFS as an SCIG packaging option for the treatment of PID. Model comparators included six IVIGs and seven SCIGs. A one-way sensitivity analysis was conducted to assess the impact of model parameters on the budget impact. Scenario analyses of alternative market share shifts and pricing were conducted to test the robustness of the model results.
Results: From the perspective of an IDN with 25 million members, the average annual expected cost per PID patient was US$73,343 for IgPro20 vials w/pump, US$60,892 for IgPro20 PFS w/pump, US$72,179 for IVIG, and US$96,581 for other SCIGs. Assuming market share uptake of 6.0% in the first year for IgPro20 PFS w/pump, rising to 8.4% by year 3, and offset by corresponding proportionate reductions in shares of the non-PFS SCIG IgPro20 vials w/pump only, the expected incremental budget impact over the 3-year horizon was savings of US$10.5 million.
Conclusion: This BIM demonstrates that uptake of subcutaneous IgPro20 PFS is expected to be associated with substantial savings for a US IDN, including drug cost savings if offset by reduced non-PFS SCIG-packaging use.
期刊介绍：
PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas:Economic analysis of healthcare interventionsHealth outcomes researchCost-of-illness studiesQuality-of-life studiesAdditional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in PharmacoEconomics -Open may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
